Background Tumors of squamous cell (SC) histology are present in 25–30% of lung cancer
patients (pts), and are more frequent in pts with a history of smoking. Erlotinib is an oral …

Background: Erlotinib is proven to prolong survival, delay symptom progression and improve
quality of life for pts with advanced NSCLC (Shepherd et al. N Engl J Med 2005; 353: 123 …

7645 Background: In patients (pts) with relapsed NSCLC, erlotinib 150 mg/d significantly
prolonged survival, delayed symptom progression, and improved quality of life versus …

8111 Background: Skin rash has been associated with increased activity of erlotinib in
retrospective analyses and plasma levels of erlotinib are lower in current vs former or non …

Purpose This phase II study (S0341) evaluated the efficacy and tolerability of single-agent
erlotinib in unselected chemotherapy-naive patients with advanced non-small cell lung …

Background: Erlotinib is epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor
which showed efficacy and tolerability in patients with advanced non-small cell lung cancer …

19012 Background: The global open-label TRUST study of erlotinib in NSCLC provides a
valuable opportunity to assess biomarker hypotheses in a large patient (pt) population. A …

Objectives Erlotinib, an inhibitor of tyrosine kinase activity of the epidermal growth factor
receptor, is effective in non-small cell lung cancer (NSCLC). Data on erlotinib use in …

Background: Erlotinib (Tarceva®), a potent, orally active inhibitor of EGFR tyrosine kinase,
significantly prolonged survival, delayed symptom progression and improved quality of life …

Maintenance therapy, commenced immediately after the completion of first-line
chemotherapy, is a promising strategy for improving treatment outcomes in patients with non …